Thomas John

Loading... 2 0 20 0 false
Credit Name
Thomas John
Full Name
John, Thomas
 
Variants
John, Tom
 
 
Personal Site
https://www.onjcancercentre.org/profile/a-prof.-tom-john
 
Loading... 3 0 20 0 false

Publications

Refined By:
Author:  Lu, Shun

Results 1-9 of 9 (Search time: 0.007 seconds).

Publication YearTitleAuthor(s)
131-Jan-2023Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.Herbst, Roy S; Wu, Yi-Long; John, Thomas ; Grohe, Christian; Majem, Margarita; Wang, Jie; Kato, Terufumi; Goldman, Jonathan W; Laktionov, Konstantin; Kim, Sang-We; Yu, Chong-Jen; Vu, Huu Vinh; Lu, Shun; Lee, Kye Young; Mukhametshina, Guzel; Akewanlop, Charuwan; de Marinis, Filippo; Bonanno, Laura; Domine, Manuel; Shepherd, Frances A; Urban, Damien; Huang, Xiangning; Bolanos, Ana; Stachowiak, Marta; Tsuboi, Masahiro
228-Jan-2023First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes.Reck, Martin; Ciuleanu, Tudor-Eliade; Cobo, Manuel; Schenker, Michael; Zurawski, Bogdan; Menezes, Juliana; Richardet, Eduardo; Bennouna, Jaafar; Felip, Enriqueta; Juan-Vidal, Oscar; Alexandru, Aurelia; Cheng, Ying; Sakai, Hiroshi; Paz-Ares, Luis; Lu, Shun; John, Thomas ; Sun, Xiaowu; Moisei, Aniela; Taylor, Fiona; Lawrance, Rachael; Zhang, Xiaoqing; Sylvester, Judi; Yuan, Yong; Blum, Steven I; Penrod, John R; Carbone, David P
31-Jun-2022Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial.Majem, Margarita; Goldman, Jonathan W; John, Thomas ; Grohe, Christian; Laktionov, Konstantin; Kim, Sang-We; Kato, Terufumi; Vu, Huu Vinh; Lu, Shun; Li, Shanqing; Lee, Kye Young; Akewanlop, Charuwan; Yu, Chong-Jen; de Marinis, Filippo; Bonanno, Laura; Domine, Manuel; Shepherd, Frances A; Atagi, Shinji; Zeng, Lingmin; Kulkarni, Dakshayini; Medic, Nenad; Tsuboi, Masahiro; Herbst, Roy S; Wu, Yi-Long
429-Apr-2022Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC.Drilon, Alexander; Chiu, Chao-Hua; Fan, Yun; Cho, Byoung Chul; Lu, Shun; Ahn, Myung-Ju; Krebs, Matthew G; Liu, Stephen V; John, Thomas ; Otterson, Gregory A; Tan, Daniel S W; Patil, Tejas; Dziadziuszko, Rafal; Massarelli, Erminia; Seto, Takashi; Doebele, Robert C; Pitcher, Bethany; Kurtsikidze, Nino; Heinzmann, Sebastian; Siena, Salvatore
5Apr-2022First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA.John, Thomas ; Sakai, Hiroshi; Ikeda, Satoshi; Cheng, Ying; Kasahara, Kazuo; Sato, Yuki; Nakahara, Yoshiro; Takeda, Masayuki; Kaneda, Hiroyasu; Zhang, Helong; Maemondo, Makoto; Minato, Koichi; Hisada, Takeshi; Misumi, Yuki; Satouchi, Miyako; Hotta, Katsuyuki; Li, Ang; Oukessou, Abderrahim; Lu, Shun
62022Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC.Wu, Yi-Long; John, Thomas ; Grohe, Christian; Majem, Margarita; Goldman, Jonathan W; Kim, Sang-We; Kato, Terufumi; Laktionov, Konstantin; Vu, Huu Vinh; Wang, Zhijie; Lu, Shun; Lee, Kye Young; Akewanlop, Charuwan; Yu, Chong-Jen; de Marinis, Filippo; Bonanno, Laura; Domine, Manuel; Shepherd, Frances A; Zeng, Lingmin; Atasoy, Ajlan; Herbst, Roy S; Tsuboi, Masahiro
71-Dec-2021A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer.Wu, Yi-Long; Tsuboi, Masahiro; John, Thomas ; Grohe, Christian; Majem, Margarita; Goldman, Jonathan W; Laktionov, Konstantin; Kim, Sang-We; Kato, Terufumi; Vu, Huu-Vinh; Lu, Shun; Lee, Kye-Young; Akewanlop, Charuwan; Yu, Chong-Jen; de Marinis, Filippo; Bonanno, Laura; Domine, Manuel; Shepherd, Frances A; Zeng, Lingmin; Hodge, Rachel; Atasoy, Ajlan; Rukazenkov, Yuri; Herbst, Roy S
8Feb-2021First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.Paz-Ares, Luis; Ciuleanu, Tudor-Eliade; Cobo, Manuel; Schenker, Michael; Zurawski, Bogdan; Menezes, Juliana; Richardet, Eduardo; Bennouna, Jaafar; Felip, Enriqueta; Juan-Vidal, Oscar; Alexandru, Aurelia; Sakai, Hiroshi; Lingua, Alejo; Salman, Pamela; Souquet, Pierre-Jean; De Marchi, Pedro; Martin, Claudio; PĂ©rol, Maurice; Scherpereel, Arnaud; Lu, Shun; John, Thomas ; Carbone, David P; Meadows-Shropshire, Stephanie; Agrawal, Shruti; Oukessou, Abderrahim; Yan, Jinchun; Reck, Martin
9Oct-2020Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.Wu, Yi-Long; Tsuboi, Masahiro; He, Jie; John, Thomas ; Grohe, Christian; Majem, Margarita; Goldman, Jonathan W; Laktionov, Konstantin; Kim, Sang-We; Kato, Terufumi; Vu, Huu-Vinh; Lu, Shun; Lee, Kye-Young; Akewanlop, Charuwan; Yu, Chong-Jen; de Marinis, Filippo; Bonanno, Laura; Domine, Manuel; Shepherd, Frances A; Zeng, Lingmin; Hodge, Rachel; Atasoy, Ajlan; Rukazenkov, Yuri; Herbst, Roy S